Speedboat Inject, Chepstow based Creo Medical’s endoscopic alternative to traditional surgery in the bowel has been added to the NHS Wales framework.
With its 5-in-1 functionality, and by using both advanced bipolar energy and microwave energy through a single power source, the miniscule device is able to remove pre-cancerous lesions in the bowel as a day case as opposed to a surgical operation.
This means that those treated by Speedboat Submucosal Dissection (SSD) typically do so without the need for general anesthetic, without the traditional side effects or aftereffects of surgery, with better patient outcomes and with patients able to be treated far quicker - often leaving the same day.
This, is turn, has significant potential benefits to NHS hospitals, with cost savings of £10k per procedure compared to traditional surgery and associated freed up bed spaces and reduced waiting lists.
The device, powered by Creo Medical’s multi-patented Kamaptive Technology, is already treating patients across the world and was recently also added to the NHS England framework – where it has been adopted by numerous hospitals. It will now be readily available to NHS Wales healthcare providers, with Creo Medical opening up further training opportunities to satisfy the post-Covid backlog of interest.
Craig Gulliford, CEO of Creo Medical said: “As a Welsh company with products which are having a transformative and positive impact on the lives of patients across the World, it’s fantastic to see Speedboat Inject awarded onto the NHS Wales framework, along with Interventional Cardiology, Radiology, Endoscopy & Surgical Urology Consumables.
“It's a challenging tender process, made even more so by Covid, so we are extremely pleased to have secured this agreement across our key product ranges.
“We will now open up increased training and mentoring opportunities in the UK to facilitate the post-Covid backlog of interest in Speedboat Inject and the associated SSD procedure and look forward to working with interested parties to help bring improved patient outcomes, cost savings and reduced waiting lists to NHS Wales.”
